Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma

Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma

Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma (HCC), a highly metastatic and recurrent cancer. However, HCC cells often develop resistance to lenvatinib, thus reducing its efficacy. This study aims to investigate the impact of STARD4, a crucial choleste...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mengting Liu, Yixin Liu, Jiahui Zheng, Xiangping An, Jiayong Wen, Fengchi Zhu, Jin Jia, Dan Guo, Nana Chen
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2025-11-01
Series:	Genes and Diseases
Subjects:	EGFR/PI3K/AKT pathway Hepatocellular carcinoma Invasion Lenvatinib resistance Migration Proliferation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304225000455
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report
by: Xiaoqing Li, et al.
Published: (2025-03-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

Effectiveness of Combination Therapy of Stereotactic Body Radiation Therapy with Lenvatinib in Advanced Hepatocellular Carcinoma
by: Alifia Sabira Putri, et al.
Published: (2025-08-01)

Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway
by: Jinlu Han, et al.
Published: (2025-09-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
by: Shinkuro Yamamoto, et al.
Published: (2025-09-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
by: Jin M, et al.
Published: (2024-11-01)

Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report
by: Yuki Hatakeyama, et al.
Published: (2025-01-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

Loss of STARD7 Triggers Metabolic Reprogramming and Cell Cycle Arrest in Breast Cancer
by: Ewelina Dondajewska, et al.
Published: (2025-08-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)
by: Giulia Puliani, et al.
Published: (2025-04-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings
by: Avinash Khadela, et al.

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
by: Lingbo Bao, et al.
Published: (2025-08-01)

miRNA-338-3p influences the liver cancer stem cells and lenvatinib resistance properties by targeting SOX4
by: Ying Yuan, et al.
Published: (2025-07-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

9th surgery decoction alleviates psoriasis-like inflammation through the downregulation of angiogenesis induced by HIF-1α and the EGFR-PI3K-AKT-mTOR pathways
by: Shengjie Zhu, et al.
Published: (2025-08-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer
by: Maciej Pawel Jankowski, et al.
Published: (2025-01-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
by: Chunyan Wang, et al.
Published: (2025-07-01)

EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study
by: Chao Zuo, et al.
Published: (2025-05-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
by: Chunbo He, et al.
Published: (2015-09-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Efek Mutasi K-RAS pada Kanker Kolorektal terhadap Terapi Antibodi Monoklonal anti EGFR
by: Farid Sastra Nagara, et al.
Published: (2008-12-01)

Cudratricusxanthone A exhibits antitumor activity and enhances chemosensitivity to cisplatin against NSCLC via targeting EGFR
by: Peiyuan Sun, et al.
Published: (2025-08-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma
by: Chenglin Zhang, et al.
Published: (2025-06-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
by: Yanjing Guo, et al.
Published: (2025-07-01)

Ethanol Extract of Adlay Hulls Suppresses Acute Myeloid Leukemia Cell Proliferation via PI3K/Akt Pathway Inhibition
by: Guangjie Li, et al.
Published: (2025-05-01)